MY177371A - Peptides - Google Patents
PeptidesInfo
- Publication number
- MY177371A MY177371A MYPI2016000224A MYPI2016000224A MY177371A MY 177371 A MY177371 A MY 177371A MY PI2016000224 A MYPI2016000224 A MY PI2016000224A MY PI2016000224 A MYPI2016000224 A MY PI2016000224A MY 177371 A MY177371 A MY 177371A
- Authority
- MY
- Malaysia
- Prior art keywords
- peptide
- peptides
- present
- pat1ially
- tshr
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 208000023328 Basedow disease Diseases 0.000 abstract 1
- 208000015023 Graves' disease Diseases 0.000 abstract 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 102000003911 Thyrotropin Receptors Human genes 0.000 abstract 1
- 108090000253 Thyrotropin Receptors Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000030741 antigen processing and presentation Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 102000051345 human TSHR Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a peptide at least pat1ially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoai1tibody formation in Graves' Disease. [No suitable figure]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201314052A GB201314052D0 (en) | 2013-08-06 | 2013-08-06 | Peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY177371A true MY177371A (en) | 2020-09-14 |
Family
ID=49224229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2016000224A MY177371A (en) | 2013-08-06 | 2014-08-06 | Peptides |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US9938329B2 (en) |
| EP (1) | EP3030259B1 (en) |
| JP (1) | JP6476181B2 (en) |
| KR (1) | KR102431507B1 (en) |
| CN (1) | CN105636980B (en) |
| AU (1) | AU2014304108B2 (en) |
| BR (1) | BR112016002572A2 (en) |
| CA (1) | CA2920321C (en) |
| CY (1) | CY1120212T1 (en) |
| DK (1) | DK3030259T3 (en) |
| ES (1) | ES2664045T3 (en) |
| GB (1) | GB201314052D0 (en) |
| HR (1) | HRP20180452T1 (en) |
| HU (1) | HUE038569T2 (en) |
| IL (1) | IL243892B (en) |
| LT (1) | LT3030259T (en) |
| MX (1) | MX369412B (en) |
| MY (1) | MY177371A (en) |
| NO (1) | NO3030259T3 (en) |
| NZ (1) | NZ717350A (en) |
| PE (1) | PE20160778A1 (en) |
| PH (1) | PH12016500218A1 (en) |
| PL (1) | PL3030259T3 (en) |
| PT (1) | PT3030259T (en) |
| RS (1) | RS57196B1 (en) |
| RU (1) | RU2676149C2 (en) |
| SG (1) | SG11201600895SA (en) |
| SI (1) | SI3030259T1 (en) |
| SM (1) | SMT201800153T1 (en) |
| UA (1) | UA120746C2 (en) |
| WO (1) | WO2015019302A2 (en) |
| ZA (1) | ZA201600729B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201314052D0 (en) * | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
| SG11201705020VA (en) * | 2014-12-24 | 2017-07-28 | Apitope Int Nv | Composition |
| WO2018127828A1 (en) * | 2017-01-04 | 2018-07-12 | Apitope International Nv | Therapeutic method using tolerogenic peptides |
| EP3369743A1 (en) * | 2017-03-01 | 2018-09-05 | advanceCOR GmbH | Cyclic peptides for the treatment of graves' disease |
| EP3622962A1 (en) | 2018-09-14 | 2020-03-18 | advanceCOR GmbH | Short cyclic peptides for the treatment of graves' disease |
| EP3982980A4 (en) * | 2019-06-12 | 2023-11-29 | BioNTech US Inc. | Neoantigen compositions and uses thereof |
| GB201909774D0 (en) | 2019-07-08 | 2019-08-21 | Apitope Tech Bristol Limited | Method |
| GB201919222D0 (en) * | 2019-12-23 | 2020-02-05 | Apitope Int Nv | Composition |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68927461T2 (en) * | 1989-12-14 | 1997-03-20 | B.R.A.H.M.S Diagnostica Gmbh, 12099 Berlin | Polypeptides with thyrotropin receptor activity, coding nucleic acid sequences for such receptors and use of these polypeptides |
| KR20030062321A (en) | 2000-08-21 | 2003-07-23 | 아피토프 테크놀러지 (브리스톨) 리미티드 | Peptide selection method |
| GB0202399D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| FR2842812A1 (en) * | 2002-07-26 | 2004-01-30 | Pf Medicament | Solubilizing hydrophobic peptides, useful e.g. in vaccines against infectious microbes or tumors, by attachment of at least three lysine residues |
| JP2006188507A (en) * | 2004-12-10 | 2006-07-20 | Tokyo Univ Of Agriculture & Technology | Method for improving protein solubility |
| EP2080772A3 (en) * | 2005-11-21 | 2009-10-07 | Dr. Fenning Biomed GmbH | Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against TSH receptor |
| NZ576032A (en) | 2006-10-12 | 2012-03-30 | Genentech Inc | Antibodies to lymphotoxin-alpha |
| GB0723712D0 (en) | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| GB0908515D0 (en) * | 2009-05-18 | 2009-06-24 | Apitope Technology Bristol Ltd | Peptide |
| GB201314052D0 (en) * | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
-
2013
- 2013-08-06 GB GB201314052A patent/GB201314052D0/en not_active Ceased
-
2014
- 2014-08-06 JP JP2016532780A patent/JP6476181B2/en active Active
- 2014-08-06 SG SG11201600895SA patent/SG11201600895SA/en unknown
- 2014-08-06 MX MX2016001744A patent/MX369412B/en active IP Right Grant
- 2014-08-06 CN CN201480053788.0A patent/CN105636980B/en active Active
- 2014-08-06 SM SM20180153T patent/SMT201800153T1/en unknown
- 2014-08-06 DK DK14772444.7T patent/DK3030259T3/en active
- 2014-08-06 MY MYPI2016000224A patent/MY177371A/en unknown
- 2014-08-06 WO PCT/IB2014/063739 patent/WO2015019302A2/en not_active Ceased
- 2014-08-06 BR BR112016002572A patent/BR112016002572A2/en not_active IP Right Cessation
- 2014-08-06 LT LTEP14772444.7T patent/LT3030259T/en unknown
- 2014-08-06 KR KR1020167005185A patent/KR102431507B1/en active Active
- 2014-08-06 US US14/910,372 patent/US9938329B2/en active Active
- 2014-08-06 NO NO14772444A patent/NO3030259T3/no unknown
- 2014-08-06 RU RU2016107873A patent/RU2676149C2/en active
- 2014-08-06 PL PL14772444T patent/PL3030259T3/en unknown
- 2014-08-06 RS RS20180316A patent/RS57196B1/en unknown
- 2014-08-06 AU AU2014304108A patent/AU2014304108B2/en active Active
- 2014-08-06 HU HUE14772444A patent/HUE038569T2/en unknown
- 2014-08-06 ES ES14772444.7T patent/ES2664045T3/en active Active
- 2014-08-06 HR HRP20180452TT patent/HRP20180452T1/en unknown
- 2014-08-06 CA CA2920321A patent/CA2920321C/en active Active
- 2014-08-06 PE PE2016000223A patent/PE20160778A1/en unknown
- 2014-08-06 NZ NZ717350A patent/NZ717350A/en unknown
- 2014-08-06 PT PT147724447T patent/PT3030259T/en unknown
- 2014-08-06 UA UAA201602098A patent/UA120746C2/en unknown
- 2014-08-06 SI SI201430666T patent/SI3030259T1/en unknown
- 2014-08-06 EP EP14772444.7A patent/EP3030259B1/en active Active
-
2016
- 2016-02-01 IL IL24389216A patent/IL243892B/en active IP Right Grant
- 2016-02-01 PH PH12016500218A patent/PH12016500218A1/en unknown
- 2016-02-02 ZA ZA2016/00729A patent/ZA201600729B/en unknown
-
2018
- 2018-02-23 US US15/903,379 patent/US10730919B2/en active Active
- 2018-03-26 CY CY20181100337T patent/CY1120212T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500218A1 (en) | Peptides | |
| ZA202200648B (en) | Immunoglobulins and uses thereof | |
| EP3412304A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| GB201201314D0 (en) | Composition | |
| IN2015KN00414A (en) | ||
| MX2022004072A (en) | Factor xi antibodies and methods of use. | |
| MX364381B (en) | Rapidly dispersible dosage form of oxcarbazepine. | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| MX2018011503A (en) | Binding proteins and methods of use thereof. | |
| PH12012501549A1 (en) | Cd127 binding proteins | |
| MY165038A (en) | Humanized antibodies that recognize alpha-synuclein | |
| MX336489B (en) | Improved recombinant human follicle-stimulating hormone. | |
| PH12013500933A1 (en) | Methods and compositions for neural disease immunotherapy | |
| WO2011044452A3 (en) | Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences | |
| NZ603196A (en) | Methods of use of soluble cd24 for therapy of rheumatoid arthritis | |
| EA201070681A1 (en) | PEPTIDES FVIII AND THEIR APPLICATION FOR THE INDUCTION OF TOLERANCE IN PATIENTS WITH HEMOPHILIA | |
| JP2014502961A5 (en) | ||
| NZ594198A (en) | Neil3 peptides and vaccines including the same | |
| MX344791B (en) | Antigen surrogates in autoimmune disease. | |
| MY201301A (en) | Glucagon receptor binding proteins and methods of use thereof | |
| MX2017008505A (en) | Composition. | |
| UA113413C2 (en) | MPHOSPH1 Peptide And Vaccine That Contains It | |
| MX369413B (en) | Peptide. | |
| PH12013501105A1 (en) | Tomm34 peptides and vaccines including the same | |
| UA124331C2 (en) | PEPTIDE ABLE TO BIND TO MOLECULE OF THE MAIN HISTORIC COMPATIBILITY COMPLEX (MHC) OF HUMAN I CLASS |